2/4
02:18 am
nerv
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
Low
Report
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
2/3
07:50 pm
nerv
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
Low
Report
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
1/26
07:00 am
nerv
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Low
Report
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
1/11
01:03 am
nerv
Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at
Wall S
Medium
Report
Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at
Wall S
11/25
01:54 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:30 am
nerv
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Low
Report
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
11/18
01:18 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.